Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
1.630
-0.040 (-2.40%)
Sep 28, 2026, 11:57 AM EDT - Market open
Skye Bioscience Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -50.49 | -55.92 | -26.57 | -37.64 | -19.48 | -8.52 |
Depreciation & Amortization | 0.69 | 0.72 | 0.3 | 0.12 | 0.11 | 0.03 |
Other Amortization | - | - | 0.6 | 0.33 | 0.49 | 0.59 |
Loss (Gain) From Sale of Assets | 0.15 | -0.36 | -1.35 | 0.3 | - | - |
Asset Writedown & Restructuring Costs | - | - | - | 21.22 | - | - |
Stock-Based Compensation | 6.3 | 7.77 | 8.32 | 0.99 | 0.63 | 0.87 |
Other Operating Activities | 3.25 | - | -3.91 | 1.2 | 6.27 | -0.1 |
Change in Accounts Payable | 1.06 | 1.4 | -0.59 | -0.7 | 0.8 | 0.52 |
Change in Other Net Operating Assets | 0.24 | 3.34 | -2.04 | 0.23 | -1.56 | 0.13 |
Operating Cash Flow | -38.81 | -43.06 | -25.24 | -13.95 | -12.74 | -6.47 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | - | -0.01 | -1.6 | -0.01 | -0.09 | -0.09 |
Sale of Property, Plant & Equipment | 0.45 | 0.36 | 1.36 | 5.53 | - | - |
Cash Acquisitions | - | - | - | 1.08 | 5.31 | - |
Investment in Securities | 22.75 | -19.85 | - | - | - | - |
Investing Cash Flow | 23.2 | -19.5 | -0.25 | 6.6 | 5.21 | -0.09 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Short-Term Debt Issued | - | - | - | 4.97 | - | - |
Long-Term Debt Issued | - | - | - | - | 0.68 | - |
Total Debt Issued | - | - | - | 4.97 | 0.68 | - |
Long-Term Debt Repaid | - | - | - | -0.26 | -0.89 | - |
Net Debt Issued (Repaid) | -0.18 | - | - | 4.71 | -0.21 | - |
Issuance of Common Stock | - | - | 90 | 12 | 0 | 14.01 |
Other Financing Activities | 0.02 | 0.03 | -6.43 | -0.27 | - | -0.94 |
Financing Cash Flow | -0.16 | 0.03 | 83.56 | 16.44 | -0.21 | 13.08 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | -15.77 | -62.53 | 58.08 | 9.09 | -7.74 | 6.51 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -38.81 | -43.07 | -26.84 | -13.96 | -12.84 | -6.57 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Per Share | -7.83 | -8.69 | -5.88 | -15.95 | -46.24 | -32.30 |
Levered Free Cash Flow | -18.71 | -22.95 | -12.94 | -11.13 | -9.44 | -3.28 |
Unlevered Free Cash Flow | -18.71 | -22.95 | -13.07 | -10.89 | -9.51 | -3.39 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash Interest Paid | 0.01 | - | 0.43 | 0.2 | 0.33 | 0.04 |
Cash Income Tax Paid | 0 | 0.01 | 0.01 | 0 | 0.01 | 0 |
Change in Working Capital | 1.29 | 4.73 | -2.63 | -0.47 | -0.76 | 0.65 |